Francisca Vazquez

New Capabilities

As of May 2026: Accepted 2026 AACR Team Science Award on behalf of DepMap team; overseeing integration of resistance models into DepMap and ResMap

Every year, hundreds of thousands of lung cancer patients start treatment with osimertinib, the leading targeted therapy for tumors driven by mutations in the EGFR gene. Most will respond, but nearly all will eventually stop responding as their cancers evolve resistance through a dozen different molecular escape routes. Until now, researchers had to work with messy lab models that made it hard to pin down which genetic change caused which failure.

Updated May 31